Mutant p53‐destabilizing drugs, such as the Hsp90 inhibitor ganetespib, are therefore considered a promising approach for treatment of p53‐mutated tumors, and a first clinical trial combining chemotherapy with ganetespib for p53‐mutated ovarian cancer patients has been initiated (Alexandrova et al, 2015; Bykov et al, 2018; Sabapathy & Lane, 2018). This evidence concerns the gene TP53 and ovarian cancer.